Other Events ·
Context Therapeutics Inc. announced positive interim efficacy and safety results from its ongoing Phase 1 clinical…
CNTXContext Therapeutics Inc.
Context Therapeutics Inc. announced positive interim efficacy and safety results from its ongoing Phase 1 clinical trial for CTIM-76, an investigational Claudin 6 x CD3 T cell engaging bispecific antibody. The company also updated its corporate presentation and hosted a conference call to discuss the clinical trial data. Context Therapeutics Inc. is a biotechnology company focused on developing investigational therapeutics for cancer.